Q1 2025 Management View CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. United Therapeutics met analysts’ revenue expectations last ...

Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. All participants on the ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.29 per share. The drugmaker posted revenue of $794.4 ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

United Therapeutics Corporation (UTHR) reported its first-quarter 2025 earnings, showcasing a strong financial performance that exceeded market expectations. The company posted an earnings per ...

United Therapeutics maintained a strong balance sheet, with $5.03 billion in cash and investments as of March 31, 2025. The company will host a conference call later today to discuss the quarter in ...